Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEX-18a Pharmacokinetics and Safety in MDS, CMML, and AML
NCT05048498Phase 1Completed
- Sponsor
- Nanexa AB
- Start
- Apr 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NEX-18 in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML), sponsored by Nanexa AB. Primary endpoint: Adverse Events and Local Tolerance. Started Apr 2021; status: completed.
02
Drugs
NEX-18
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05048498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05048498.